PWE-012 In vitro characterisation of aberrantly glycosylated MUC1 binding-PS1 photoimmunoconjugates for oesophageal adenocarcinoma targeted photodynamic therapy in primary and metastatic disease: Abstract PWE-012 Figure 1

Introduction

Most patients with oesophageal adenocarcinoma (OA) are unfit for curative treatment but are fit for photodynamic therapy (PDT). PDT has been limited by poor tumour selectivity, poor tissue penetration of light and protracted side effects. These restrictions may be overcome with targeted PDT. We have previously demonstrated aberrantly glycosylated MUC1 (AG-MUC1), bound by humanised anti-human milk-fat globule-1 (Hu-HMFG1)...